Education Publications Contact Information drcatalona.com

William J. Catalona, MD
Professor

Dr. Catalona joined the Northwestern faculty in 2003. He is known for having been the first to show that a simple blood test that measures levels of prostate-specific antigen (PSA) is the most accurate method for detecting prostate cancer and for having developed the "free" PSA test as a means of improving the accuracy of prostate cancer screening.

Dr. Catalona is currently conducting research into the genetics of prostate cancer which could lead to new tests for the disease as well as possible new means of treating or preventing prostate cancer. He specializes in prostate cancer surgery and is recognized as an expert in performing the "nerve-sparing" radical prostatectomy that can preserve sexual potency. 

In addition to his appointment as Professor of Urology, Dr. Catalona also serves as Director of the Clinical Prostate Cancer Program of Northwestern's Robert H. Lurie Comprehensive Cancer Center. 

Education

Undergraduate: Otterbein College, Westerville, OH
Medical school: Yale Medical School, New Haven, CT
Internship: Yale-New Haven Hospital, New Haven, CT
Surgery residency: University of California, San Francisco, CA
Clinical Associate: National Institutes of Health, National Cancer Institute, Bethesda, MD
Urology residency: Johns Hopkins Hospital, Baltimore, MD 

Selected Publications
The following publications are selected from a total of 338 journal articles. For more information on Dr. Catalona's scholarly productivity, please visit http://www.drcatalona.com or contact his office.

Journal Articles

1. Xu JF, Meyers DA, Sterling DA, Zheng SQL, Catalona WJ, Cramer SD, Bleecker ER, Ohar J. Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes. Cancer Epidemiol Biomarkers Prev. 11(7):664-9. 2002.
2. Roehl KA, Antenor JAV, Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol. 167(6):2435-9. 2002.
3. Catalona WJ. Early onset prostate cancer: predictors of clinical grade. Editorial comment. J Urol. 167(4):1663. 2002.
4. Casey G, Neville PJ, Plummer SJ, Xiang Y, Krumroy LM, Klein EA, Catalona WJ, Nupponen N, Carpten JC, Trent JM, Silverman RH, Witte JS. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet. 32(4): 581-3. 2002.
5. Krumholtz JS, Carvalhal GF, Ramos CG, Smith DS, Thorson P, Yan Y, Humphrey PA, Roehl KA, Catalona WJ. PSA cutoff of 2.6 ng/ml for prostate cancer screening is associated with favorable pathologic tumor features. Urology. 60(3):469-73; discussion 473-4. 2002.
6. Neville PJ, Conti DV, Krumroy LM, Catalona WJ, Suarez BK, Witte JS, Casey G. Prostate cancer aggressiveness locus on chromosome segment 19q12-q13.1 identified by linkage and allelic imbalance studies. Genes Chromosomes Cancer. 36(4):332-9. 2003.
7. Neville PJ, Conti DV, Paris PL, Levin H, Catalona WJ, Suarez BK, Witte JS, Casey G. Prostate cancer aggressiveness locus on chromosome 7q32-q33 identified by linkage and allelic imbalance studies. Neoplasia. 4:(5)424-31. 2002.
8. Catalona WJ. Informed consent for prostate-specific antigen screening. Editorial. Urology. 61(1):17-9. 2003.
9. Catalona WJ, Bartsch G, Rittenhouse HG, Evans CL, Linton HJ, Amirkhan A, Horninger W, Klocker H, Mikolajczyk SD. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol. 170(6 Pt 1):2181-5. 2003.
10. Witte JS, Suarez BK, Thiel B, Lin J, Yu A, Banerjee TK, Burmester JK, Casey G, Catalona WJ. Genome-wide scan of brothers: replication and fine mapping of prostate cancer susceptibility and aggressiveness loci. Prostate. 57(4):298-308. 2003.
11. Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med. 349(4):335-42. 2003.
12. Cramer SD, Chang BL, Rao A, Hawkins GA, Zheng SL, Wade WN, Cooke RT, Thomas LN, Bleecker ER, Catalona WJ, Sterling DA, Meyers DA, Ohar J, Xu J. Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels. J Natl Cancer Inst. 95(14):1044-53. 2003.
13. Kibel AS, Suarez BK, Belani J, Oh J, Webster R, Brophy-Ebbers M, Guo C, Catalona WJ, Picus J, Goodfellow PJ. CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. Cancer Res. 63(9):2033-6. 2003.
14. Mikolajczyk SD, Catalona WJ, Evans CL, Linton HJ, Millar LS, Marker KM, Katir D, Amirkhan A, Rittenhouse HG. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem. 50(6):1017-29. 2004.
15. Han M, Gann PH, Catalona WJ. Prostate-specific antigen and screening for prostate cancer. Med Clin North Am. 88(2):245-65. 2004.
16. Zhu H, Roehl KA, Antenor JA, Catalona WJ. Clinical value of longitudinal free-to-total prostate specific antigen ratio slope to diagnosis of prostate cancer. J Urol. 171(2 Pt 1):661-3. 2004.
17. Han M, Nadler RB, Catalona WJ, Thrasher JB, Tewari A, Menon M. Radical prostatectomy: should the retropubic approach remain the standard of care? Contemporary Urology. 38-46. 2004.
18. Han M, Catalona WJ. What is the best PSA prompt for biopsy?  AUA News. 9:30-1. 2004.
19. Catalona WJ. No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam).  Editorial comment. Urology. 63(5):897-8. 2004.
20. Catalona WJ, Bartsch G, Rittenhouse HG, Evans CL, Linton HJ, Horniger W, Klocker H, Mikolajczyk SD. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol. 171(6 Pt 1):2239-44. 2004.
21. Antenor JAV, Han M, Roehl KA, Nadler RB, Catalona WJ. Relation between initial PSA level and subsequent prostate cancer detection in a longitudinal screening population. J Urol. 172(1):90-3. 2004.
22. Ramos CG, Roehl KA, Antenor JAV, Humphrey PA, Catalona WJ.  Percent carcinoma in prostatectomy specimen is associated with risk for recurrence after radical prostatectomy in patients with pathologically organ confined prostate cancer. J Urol. 172(1):137-40. 2004.
23. Cross D, Redding DJ, Salzman SA, Zhang KQ, Catalona WJ, Burke J, Burmester JK. Expression and initial promoter characterization of PCAN1 in retinal tissue and prostate cell lines. Med Oncol. 21(2):145-53. 2004.
24. D’Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351(2):125-35. 2004.
25. Roehl KA, Han M, Ramos CG, Antenor JAV, Catalona WJ. Cancer progression and survival rate following anatomic radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 172(3):910-14. 2004.

Contact Information